Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease.

NCT02036645 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02036645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02036645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease.
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
February 4, 2014
Completion date
September 15, 2016
Enrollment
77 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

healthy elderly, mild-moderate alzheimer's disease